Advisor Group Holdings, Inc. Mersana Therapeutics, Inc. Transaction History

Advisor Group Holdings, Inc.

$42.1 Billion
Q1 2025

A detailed history of Advisor Group Holdings, Inc. transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 3,334 shares of MRSN stock, worth $1,266. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,334

Previous 932 257.73%

Holding current value

$1,266

Previous $1,000 -0.0%

% of portfolio

0.0%

Previous 0.0%

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 12, 2025	BUY	$0.34 - $1.4 $816 - $3,362	2,402 Added 257.73%	3,334 $1,000
Q4 2024 Feb 07, 2025	SELL	$1.42 - $2.68 $3,550 - $6,700	-2,500 Reduced 72.84%	932 $1,000
Q3 2024 Nov 13, 2024	SELL	$1.23 - $2.25 $54 - $99	-44 Reduced 1.27%	3,432 $6,000
Q2 2024 Aug 13, 2024	SELL	$2.0 - $4.45 $604 - $1,343	-302 Reduced 7.99%	3,476 $6,000
Q1 2024 May 10, 2024	SELL	$2.16 - $5.94 $123 - $338	-57 Reduced 1.49%	3,778 $16,000
Q4 2023 Feb 12, 2024	SELL	$1.11 - $2.34 $102 - $215	-92 Reduced 2.34%	3,835 $8,000
Q3 2023 Nov 13, 2023	BUY	$1.06 - $3.91 $733 - $2,705	692 Added 21.39%	3,927 $4,000
Q2 2022 Aug 10, 2022	BUY	$2.84 - $5.0 $335 - $590	118 Added 3.79%	3,235 $15,000
Q1 2022 May 04, 2022	BUY	$3.74 - $6.63 $8,377 - $14,851	2,240 Added 255.42%	3,117 $12,000
Q3 2021 Nov 05, 2021	BUY	$8.56 - $14.47 $539 - $911	63 Added 7.74%	877 $8,000
Q2 2021 Aug 02, 2021	BUY	$13.28 - $18.07 $7,078 - $9,631	533 Added 189.68%	814 $11,000
Q1 2021 May 13, 2021	BUY	$15.31 - $26.52 $3,536 - $6,126	231 Added 462.0%	281 $5,000
Q2 2020 Aug 14, 2020	SELL	$5.24 - $23.4 $2,096 - $9,360	-400 Reduced 88.89%	50 $1,000
Q1 2020 May 18, 2020	BUY	$4.41 - $9.28 $1,984 - $4,176	450 New	450 $3,000

Others Institutions Holding MRSN

# of Institutions

116

Shares Held

101M

Call Options Held

16.3K

Put Options Held

13K

View Full List

About Mersana Therapeutics, Inc.

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $36.9M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

More about MRSN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Advisor Group Holdings, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Advisor Group Holdings, Inc. with notifications on news.

Account

Advisor Group Holdings, Inc. Mersana Therapeutics, Inc. Transaction History